Survival outcomes of ibrutinib–rituximab therapy in young, treatment-naïve patients with CLL outshined rates seen with the gold standard of care regimen.
Survival outcomes of ibrutinib–rituximab therapy in young, treatment-naïve patients with CLL outshined rates seen with the gold standard of care regimen.
Results from a recent trial highlight the promising potential of obinutuzumab plus ibrutinib as a promising new first-line treatment option for patients with CLL or SLL.
Results from a recent trial highlight the promising potential of obinutuzumab plus ibrutinib as a promising new first-line treatment option for patients with CLL or SLL.